Our Science
BioMarin is a pharmaceutical company
that develops and provides innovative biopharmaceuticals
for rare diseases.
About Our Science
BioMarin is a pharmaceutical company
that develops and provides innovative biopharmaceuticals for rare diseases.
We provide breakthrough treatments to patients confronting unmet medical needs.
For patients suffering from a rare disease, a phase before getting a diagnosis is very important.
Often, they find a very limited number of therapeutic options or none even after being diagnosed, and BioMarin is committed to deliver therapies to such patients.
At the core of BioMarin are research & development that enables fulfilment of this commitment, as well as efficiency and speed in manufacturing efforts.
BioMarin is actively engaged in development of new innovative drugs focusing on treatment of rare diseases.
Currently providing three formulas for three diseases in Japan, we are also developing multiple preclinical drug candidates and running multiple clinical trials.
Since the foundation in 1997, BioMarin has developed multiple biopharmaceuticals for rare diseases.
This reflects our passion and dedication to patients confronting unmet medical needs.
Our Products Available
In Japan, BioMarin obtained an approval for and markets five products currently.
Mucopolysaccharidosis ⅣA therapeutic agent
Mucopolysaccharidosis Ⅵ therapeutic agent
Drug for neuronal ceroid lipofuscinosis type 2
Achondroplasia drug
Phenylketonuria treatment agent
As of May 2023
Our Pipeline
Japan domestic
Please check the National Institute of Public Health clinical research information portal site for details of drug development status in Japan (including those other than our company).
US headquarters
- Please visit our head office site.
